



# Impact of former smoking exposure on airway eosinophilic activation and autoimmunity in patients with severe asthma

Ditte K. Klein<sup>1,3</sup>, Alexander Silberbrandt<sup>1,3</sup>, Laurits Frøssing<sup>1</sup>, Morten Hvidtfeldt , Anna von Bülow<sup>1</sup>, Parameswaran Nair<sup>2</sup>, Manali Mukherjee  and Celeste Porsbjerg<sup>1</sup>

<sup>1</sup>Respiratory Research Unit, Dept of Respiratory Medicine, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark. <sup>2</sup>Dept of Medicine, Division of Respiriology, McMaster University and Firestone Institute for Respiratory Health, St Joseph's Healthcare, Hamilton, ON, Canada. <sup>3</sup>Both authors contributed equally to this manuscript.

Corresponding author: Celeste Porsbjerg ([celeste.porsbjerg@regionh.dk](mailto:celeste.porsbjerg@regionh.dk))



Shareable abstract (@ERSpublications)

In patients with severe asthma, former smoking exposure is associated with airway eosinophil activation and autoimmunity towards eosinophils and macrophages, as well as an incomplete anti-inflammatory response to systemic corticosteroids. <https://bit.ly/3sTBjIF>

**Cite this article as:** Klein DK, Silberbrandt A, Frøssing L, *et al.* Impact of former smoking exposure on airway eosinophilic activation and autoimmunity in patients with severe asthma. *Eur Respir J* 2022; 60: 2102446 [DOI: 10.1183/13993003.02446-2021].

This single-page version can be shared freely online.

Copyright ©The authors 2022.  
For reproduction rights and  
permissions contact  
[permissions@ersnet.org](mailto:permissions@ersnet.org)

Received: 9 Sept 2021  
Accepted: 14 Feb 2022

## Abstract

**Introduction** Severe eosinophilic asthma is characterised by frequent exacerbations and a relative insensitivity to steroids. Experimentally, smoking may induce eosinophilic airway inflammation, but the impact in patients with severe asthma is not clear.

**Objective** To investigate the association between smoking exposure in patients with severe asthma, and eosinophilic inflammation and activation, as well as airway autoimmunity and steroid responsiveness.

**Methods** Patients with severe asthma according to European Respiratory Society/American Thoracic Society criteria were assessed with sputum samples, analysed by cell differential count, and for the presence of free eosinophil granules (FEGs), autoantibodies against eosinophil peroxidase (EPX) and macrophage receptor with collagenous structure (MARCO). A subgroup of patients with eosinophilic airway inflammation was re-assessed after a 2-week course of prednisolone.

**Results** 132 severe asthmatics were included in the study. 39 (29.5%) patients had  $\geq 10$  pack-years of smoking history: 36 (27.3%) were former smokers and three (2.3%) current smokers; and 93 (70.5%) had  $< 10$  pack-years exposure. Eosinophilic airway inflammation was more prevalent among patients with  $\geq 10$  pack-years (66.7%), compared to patients with  $< 10$  pack-years (38.7%,  $p=0.03$ ), as was the level of FEGs ( $p=0.001$ ) and both anti-EPX and anti-MARCO ( $p<0.05$  and  $p<0.0001$ , respectively). Omitting current smokers did not affect these associations. Furthermore, prednisolone reduced, but did not normalise, sputum eosinophils in patients with a  $\geq 10$  pack-year smoking history.

**Conclusion** In patients with severe asthma, a former smoking history is associated with eosinophilic airway inflammation and activation and relative insensitivity to steroids, as well as airway autoimmunity.